Evidence map›Paper›PMID 40040716›Full record

ArticleFrontiers in immunology2025

Recognition of MR1-antigen complexes by TCR Vγ9Vδ2.

José Pedro Loureiro, Alessandro Vacchini, Giuliano Berloffa, Jan Devan, Verena Schaefer, Vladimir Nosi, Rodrigo Colombo, Aisha Beshirova, Giulia Montanelli, Benedikt Meyer and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

José Pedro LoureiroExperimental Immunology, Department of Biomedicine, University Hospital and University of Basel, Basel, Switzerland.
Alessandro VacchiniExperimental Immunology, Department of Biomedicine, University Hospital and University of Basel, Basel, Switzerland.
Giuliano BerloffaExperimental Immunology, Department of Biomedicine, University Hospital and University of Basel, Basel, Switzerland.
Jan DevanExperimental Immunology, Department of Biomedicine, University Hospital and University of Basel, Basel, Switzerland.
Verena SchaeferExperimental Immunology, Department of Biomedicine, University Hospital and University of Basel, Basel, Switzerland.
Vladimir NosiExperimental Immunology, Department of Biomedicine, University Hospital and University of Basel, Basel, Switzerland.
Rodrigo ColomboExperimental Immunology, Department of Biomedicine, University Hospital and University of Basel, Basel, Switzerland.
Aisha BeshirovaExperimental Immunology, Department of Biomedicine, University Hospital and University of Basel, Basel, Switzerland.
Giulia MontanelliExperimental Immunology, Department of Biomedicine, University Hospital and University of Basel, Basel, Switzerland.
Benedikt MeyerImmunodeficiency Laboratory, Department of Biomedicine, University Hospital and University of Basel, Basel, Switzerland.
Timothy SharpeBiozentrum, University of Basel, Basel, Switzerland.
Andrew ChancellorExperimental Immunology, Department of Biomedicine, University Hospital and University of Basel, Basel, Switzerland.
Mike RecherImmunodeficiency Laboratory, Department of Biomedicine, University Hospital and University of Basel, Basel, Switzerland.
Lucia MoriExperimental Immunology, Department of Biomedicine, University Hospital and University of Basel, Basel, Switzerland.
Gennaro De LiberoExperimental Immunology, Department of Biomedicine, University Hospital and University of Basel, Basel, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The TCR-mediated activation of T cells expressing the TCR Vγ9Vδ2 relies on an innate-like mechanism involving the butyrophilin 3A1, 3A2 and 2A1 molecules and phospho-antigens, without the participation of classical antigen-presenting molecules. Whether TCR Vγ9Vδ2 cells also recognize complexes composed of antigens and antigen-presenting molecules in an adaptive-like manner is unknown. Here, we identify MR1-autoreactive cells expressing the TCR Vγ9Vδ2. This MR1-restricted response is antigen- and CDR3δ-dependent and butyrophilin-independent. TCR gene transfer reconstitutes MR1-antigen recognition, and engineered TCR Vγ9Vδ2 tetramers interact with soluble MR1-antigen complexes in an antigen-dependent manner. These cells are present in healthy individuals with low frequency and are mostly CD8

Indexed as

Histocompatibility Antigens Class IMinor Histocompatibility AntigensReceptors, Antigen, T-Cell, gamma-deltaButyrophilinsHumansLymphocyte ActivationMaleT-LymphocytesButyrophilinsHistocompatibility Antigens Class IMinor Histocompatibility AntigensMR1 protein, humanReceptors, Antigen, T-Cell, gamma-deltaadaptive immunityantigen recognitionMR1TCR γδVγ9Vδ2

Identifiers

PMID40040716
PMCPMC11876030

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.